Azitra Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2
Azitra announced the completion of Cohort 1 and clearance for Cohort 2 of a clinical trial evaluating drug candidate ATR04-484 as a treatment for EGFR inhibitor-induced skin rash, following a safety review. The advancement marks a significant milestone for the company's live biotherapeutic program addressing a common side effect in oncology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed